<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVETo assess the effect of two <z:chebi fb="0" ids="35526">hypoglycemic drugs</z:chebi> on ischemic preconditioning (<z:chebi fb="76" ids="53004">IPC</z:chebi>) patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD).RESEARCH DESIGN AND METHODSWe performed a prospective study of 96 consecutive patients allocated into two groups: 42 to group repaglinide (R) and 54 to group vilgagliptin (V) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent two consecutive exercise tests (ET1 and ET2) in phase 1 without drugs </plain></SENT>
<SENT sid="2" pm="."><plain>In phase 2, 1 day after ET1 and -2, 2 mg repaglinide three times daily or 50 mg vildagliptin twice daily was given orally to patients in the respective group for 6 days </plain></SENT>
<SENT sid="3" pm="."><plain>On the seventh day, 60 min after 6 mg repaglinide or 100 mg vildagliptin, <z:hpo ids='HP_0000001'>all</z:hpo> patients underwent two consecutive exercise tests (ET3 and ET4).RESULTSIn phase 1, <z:chebi fb="76" ids="53004">IPC</z:chebi> was demonstrated by improvement in the time to 1.0 mm ST-segment <z:hpo ids='HP_0000716'>depression</z:hpo> and rate pressure product (RPP) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients developed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in ET3; however, 83.3% of patients in group R experienced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> earlier in ET4, without significant improvement in RPP, indicating the cessation of <z:chebi fb="76" ids="53004">IPC</z:chebi> (P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>In group V, only 28% of patients demonstrated <z:chebi fb="76" ids="53004">IPC</z:chebi> cessation, with 72% still having the protective effect (P &lt; 0.0069).CONCLUSIONSRepaglinide eliminated myocardial <z:chebi fb="76" ids="53004">IPC</z:chebi>, probably by its effect on the K(ATP) channel </plain></SENT>
<SENT sid="6" pm="."><plain>Vilgagliptin did not damage this protective mechanism in a relevant way in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and CAD, suggesting a good alternative treatment in this population </plain></SENT>
</text></document>